Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 1032350-13-2] MK-2206 dihydrochloride

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-10358
Brand:	MCE
CAS:	1032350-13-2

Overview

MDL	MFCD14584463
Molecular Weight	480.39
Molecular Formula	C25H23Cl2N5O
SMILES	O=C1N2C(C3=CC(C4=CC=CC=C4)=C(N=C3C=C2)C5=CC=C(C6(N)CCC6)C=C5)=NN1.Cl.Cl

For research use only. We do not sell to patients.

222 Publications Citing Use of MCE

[1]Nature. 2018 Aug;560(7719):499-503.
[2]Cell. 2014 Feb 13;156(4):771-85.
[3]Science. 2022 Jul 8;377(6602):eabg9302.
[4]Mol Cancer. 2019 Nov 21;18(1):167.
[5]Cancer Cell. 2018 Jun 11;33(6):1061-1077.e6.
[6]Cell Stem Cell. 2019 Dec 5;25(6):754-767.e9.
[7]Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
[8]Mol Cell. 2022 May 13;S1097-2765(22)00393-8.
[9]Mol Cell. 2021 Jan 21;81(2):370-385.e7.
[10]Signal Transduct Target Ther. 2021 Jun 18;6(1):234.
[11]Sci Adv. 2022 Jan 21;8(3):eabh2635.
[12]Nat Chem Biol. 2017 Jan;13(1):38-45.
[13]Nat Commun. 2022 Nov 29;13(1):7345.
[14]Nat Commun. 2022 Aug 2;13(1):4495.
[15]Nat Commun. 2022 Apr 19;13(1):2136.
[16]Nat Commun. 2021 Jun 30;12(1):4050.
[17]Nat Commun. 2018 May 8;9(1):1816.
[18]Cell Death Differ. 2023 Jan 13.
[19]Cell Death Differ. 2021 Mar;28(3):1026-1040.
[20]J Mater Sci Technol. 13 August 2022.
[21]Redox Biol. 2021 Dec 18;49:102217.
[22]Cancer Res. 2021 Mar 8;canres.3232.2020.
[23]Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2996-3005.
[24]Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4338-47.
[25]Mol Ther Nucleic Acids. 20 July 2022.
[26]Mol Ther Nucleic Acids. May 20, 2022.
[27]J Cell Biol. 2021 Oct 4;220(10):e202010118.
[28]Cell Mol Gastroenterol Hepatol. 2021;11(3):683-696.
[29]Bioact Mater. 2022 Mar 24;18:116-127.
[30]Cell Syst. 2020 Jan 22;10(1):66-81.e11.
[31]Cell Syst. 2020 Jan 22;10(1):66-81.e11.
[32]Theranostics. 2021 Jan 19;11(7):3392-3416.
[33]Theranostics. 2020 Aug 6;10(21):9899-9912.
[34]Theranostics. 2020 Feb 3;10(6):2859-2871.
[35]Theranostics. 2018 Feb 15;8(7):2044-2060.
[36]Cell Mol Immunol. 2023 Jan 5.
[37]Cell Rep. 2023, 42(1): 111916.
[38]Cell Rep. 2022 Dec 27;41(13):111891.
[39]Cell Rep. 2022 Feb 15;38(7):110392.
[40]Oncogene. 2020 Oct;39(41):6451-6467.
[41]Oncogene. 2019 Jun;38(26):5250-5264.
[42]Oncogene. 2018 Nov;37(45):5997-6009.
[43]Oncogene. 2017 Aug 10;36(32):4585-4596.
[44]Cancer Lett. 2023 Jan 18;556:216063.
[45]Cancer Lett. 2022 Jul 12;215826.
[46]Cancer Lett. 2021 Apr 21;S0304-3835(21)00172-5.
[47]Cancer Lett. 2020 Apr 10;475:53-64.
[48]Eur J Cancer. 2022 May 19;170:91-102.
[49]J Invest Dermatol. 2019 Jan;139(1):71-80.
[50]Acta Pharm Sin B. 2021 Jun;11(6):1592-1606.
[51]Acta Pharm Sin B. 2021 Jan;11(1):71-88.
[52]Elife. 2021 Jul 13;10:e66942.
[53]J Exp Clin Cancer Res. 2022 Jan 26;41(1):38.
[54]J Exp Clin Cancer Res. 2021 Dec 10;40(1):390.
[55]J Exp Clin Cancer Res. 2021 Aug 20;40(1):262.
[56]J Exp Clin Cancer Res. 2019 Feb 13;38(1):76.
[57]J Exp Clin Cancer Res. 2018 Apr 3;37(1):77.
[58]Mol Oncol. 2023 Jan 27.
[59]Mol Oncol. 2022 Jul 19.
[60]Sci Total Environ. 2021 Nov 10;794:148732.
[61]J Nanobiotechnology. 2022 Sep 24;20(1):422.
[62]Cell Death Dis. 2022 Sep 29;13(9):838.
[63]Cell Death Dis. 2022 Apr 19;13(4):370.
[64]Cell Death Dis. 2020 May 11;11(5):353.
[65]Cell Death Dis. 2019 Aug 13;10(8):609.
[66]Cell Death Dis. 2019 May; 10(5): 329.
[67]Cell Death Dis. 2018 Oct 3;9(10):1015.
[68]Free Radic Biol Med. 2022 Oct 19;S0891-5849(22)00930-3.
[69]Cancers. 2020 Jul 16;12(7):1918.
[70]Stem Cells. 2019 Dec;37(12):1567-1580.
[71]Oncoimmunology. 2018 Aug 6;7(10):e1488565.
[72]Br J Cancer. 2017 Sep 26;117(7):974-983.
[73]Cell Prolif. 2021 May 5;e13045.
[74]J Cell Physiol. 2021 Aug;236(8):5818-5831.
[75]Exp Mol Med. 2022 Nov 24.
[76]Neurobiol Dis. 2019 Apr;124:520-530.
[77]Cell Oncol. 2021 Jul 28.
[78]Front Cell Dev Biol. 2021 Apr 14;9:649277.
[79]Am J Cancer Res. 2021 Apr 15;11(4):1557-1571.
[80]Stem Cell Res Ther. 2022 Jan 10;13(1):13.
[81]Stem Cell Res Ther. 2021 Jan 26;12(1):88.
[82]Hum Mol Genet. 2017 Sep 15;26(18):3553-3563.
[83]Oxid Med Cell Longev. 2022
[84]Acta Pharmacol Sin. 2018 Nov;39(11):1787-1796.
[85]Clin Epigenetics. 2018 May 23;10:69.
[86]Antioxidants (Basel). 2022 Oct 18;11(10):2050.
[87]Antioxidants (Basel). 2022, 11(10), 2050.
[88]FASEB J. 2023 Feb;37(2):e22744.
[89]FASEB J. 2020 Jan;34(1):1481-1496.
[90]Cancer Sci. 2018 Apr;109(4):944-955.
[91]J Immunol. 2020 Oct 15;205(8):2255-2264.
[92]Int J Biol Sci. 2023; 19(1): 204-224.
[93]Int J Biol Sci. 2021 Apr 24;17(7):1821-1836.
[94]Aging. 2021 Apr 11;13(7):10672-10687.
[95]Aging. 2020 Jun 12;12(12):11717-11731.
[96]Genes Dis. 2021 Aug 17;9(2):562-575.
[97]Endocr Relat Cancer. 2019 Aug;26(8):699-712.
[98]Food Chem Toxicol. 2018 Oct;120:500-509.
[99]Mol Cancer Res. 2020 Mar;18(3):414-423.
[100]Int J Mol Sci. 2022 Aug 8;23(15):8798.
[101]Nutrients. 2022, 14(16), 3395.
[102]Biomed Pharmacother. 2021, 111089.
[103]Biomed Pharmacother. 2019 Dec;120:109498.
[104]J Cell Mol Med. 2021 Sep 30.
[105]J Cell Mol Med. 2020 Jun;24(12):6869-6882.
[106]iScience. 2021 Sep 25;24(10):103173.
[107]FEBS J. 2019 Apr;286(7):1305-1318.
[108]Cells. 2022 Nov 5;11(21):3505.
[109]Phytomedicine. 2022 Jul;101:154121.
[110]Phytomedicine. 23 August 2021, 153687.
[111]J Biol Chem. 2022 Dec 14;102798.
[112]J Biol Chem. 2022 May 13;102030.
[113]J Biol Chem. 2012 Mar 23;287(13):9742-52.
[114]J Cell Biochem. 2019 Oct;120(10):17744-17756.
[115]J Cell Biochem. 2018 May;119(5):3885-3891.
[116]Front Microbiol. 12 September 2022.
[117]J Agric Food Chem. 2022 Feb 1.
[118]J Agric Food Chem. 2019 Sep 4;67(35):9805-9811.
[119]Front Mol Biosci. 08 July 2021.
[120]Cancer Cell Int. 2022 Jan 11;22(1):18.
[121]Cancer Cell Int. 2021 Apr 26;21(1):235.
[122]Food Funct. 2021 Mar 9.
[123]Bone. 2021 Oct 12;116231.
[124]J Transl Med. 2022 Nov 5;20(1):509.
[125]J Transl Med. 2022 Jul 21;20(1):325.
[126]Cell Death Discov. 2020 Jul 6;6:56.
[127]Toxicology. 2022 Oct;480:153326.
[128]Cell Immunol. 11 January 2022, 104475.
[129]Sci Rep. 2022 Aug 13;12(1):13796.
[130]Sci Rep. 2020 May 7;10(1):7714.
[131]Sci Rep. 2018 Oct 18;8(1):15454
[132]Cell Signal. 2020 Dec 25;109900.
[133]Int Immunopharmacol. 2021 Oct 26;101(Pt A):108264.
[134]Int Immunopharmacol. 2021 Jan 30;93:107395.
[135]Front Cardiovasc Med. 2021 Sep 3;8:687540.
[136]Int J Oncol. 2017 Aug;51(2):625-632.
[137]Mediat Inflamm. 2019 Oct 7;2019:6168340.
[138]Am J Physiol Gastrointest Liver Physiol. 2022 May 31.
[139]Cell Cycle. 2022 Aug 25;1-12.
[140]J Ethnopharmacol. 24 December 2021, 114937.
[141]J Ethnopharmacol. 2021, 114224.
[142]Int J Biochem Cell Biol. 2023 Feb;155:106359.
[143]Int J Biochem Cell Biol. 2018 Jun;99:43-51.
[144]Int J Biochem Cell Biol. 2018 Apr;97:16-27.
[145]Mol Pharmacol. 2019 Dec;96(6):862-870.
[146]Cancer Biol Ther. 2022 Jan 9;1-14.
[147]Life Sci. 2022 Aug 26;120907.
[148]Life Sci. 2020 Nov 1;260:118470.
[149]Life Sci. 2020 May 15;249:117503.
[150]Life Sci. 2020 Mar 15;245:117328.
[151]J Biochem Mol Toxicol. 2019 Nov;33(11):e22391.
[152]J Cancer. 2018 Jun 14;9(14):2480-2491.
[153]J Biomed Mater Res A. 2020 Aug 28.
[154]Oncol Rep. 2019 Aug;42(2):849-856.
[155]Exp Cell Res. 2020 Dec 1;397(1):112341.
[156]Brain Res Bull. 2020 Sep;162:166-179.
[157]Toxicol Appl Pharmacol. 2022 Mar 5;115969.
[158]Ann Transl Med. 2021 Apr;9(7):533.
[159]Molecules. 2022 Dec 5;27(23):8568.
[160]Eur J Pharmacol. 2019 May 15;851:69-79.
[161]Reproduction. 2022 Feb 1;REP-21-0282.
[162]Exp Eye Res. 2018 Jul;172:10-20.
[163]Biochem Biophys Res Commun. 2022.
[164]Biochem Biophys Res Commun. 3 October 2022.
[165]Biochem Biophys Res Commun. 2022 Jun 25;610:170-175.
[166]Biochem Biophys Res Commun. 2020 Dec 12;534:121-127.
[167]Biochem Biophys Res Commun. 2019 Feb 26;510(1):97-103.
[168]Biochem Biophys Res Commun. 2017 Aug 5;489(4):484-489.
[169]Cytokine. 2020 May;129:155046.
[170]Biosci Rep. 2019 Dec 20;39(12):BSR20191041.
[171]ACS Omega. 2020 Feb 13;5(7):3709-3716.
[172]Peptides. 2018 Sep;107:39-44.
[173]Virology. 2022 Sep 26;576:83-95.
[174]PLoS One. 2016 Jan 28;11(1):e0147682.
[175]Radiat Res. 2018 Aug;190(2):204-215.
[176]R Soc Open Sci. 2020 Jul 8;7(7):200635.
[177]Biol Trace Elem Res. 2022 Mar 21.
[178]Life Sci Alliance. 2022 Jun 2;5(10):e202101330.
[179]Thorac Cancer. 2022 May 10.
[180]J Mol Histol. 2019 Aug;50(4):369-374.
[181]J Pain Res. 2020 Dec 1;13:3195-3206.
[182]PeerJ. October 25, 2022.
[183]Oncol Lett. 2020 Dec;20(6):398.
[184]Clin Exp Pharmacol Physiol. 2019 Sep;46(9):861-871.
[185]FEBS Open Bio. 2021 May 1.
[186]Mol Med Rep. 2022 Jan;25(1):17.
[187]Mol Med Rep. 2021 Jul;24(1):508.
[188]Bosn J Basic Med Sci. 2021 Aug 1;21(4):434-446.
[189]Exp Ther Med. 2022 Jun;23(6):413.
[190]Exp Ther Med. February 22, 2022.
[191]Exp Ther Med. July 29, 2021.
[192]Exp Ther Med. 2019 May;17(5):3530-3538.
[193]Dev Growth Differ. 2016 Apr;58(3):280-92.
[194]Cell Reprogram. 2021 Oct 22.
[195]In Vitro Cell Dev Biol Anim. 2021 Oct 28.
[196]Acta Otolaryngol. 2021 Dec 28;1-7.
[197]Mol Biol Rep. 2022 Nov 4.
[198]Mol Biol Rep. 2021 Nov 3.
[199]Curr Med Sci. 2022 Apr;42(2):387-396.
[200]Indian J Pharm Sci. 2022.
[201]Int J Clin Exp Pathol. 2017;10(3):3033-3042.
[202]Int J Clin Exp Med. 2016;9(9):18513-18518.
[203]Research Square Print. October 11th, 2022.
[204]Patent. US20220288067A1.
[205]Research Square Print. August 22nd, 2022.
[206]Research Square Preprint. 2022 Feb.
[207]University of Zürich. Department of Dermatology. 2021 Dec.
[208]Research Square Preprint. 2021 Aug.
[209]Research Square Preprint. 2020 Nov.
[210]bioRxiv. 2020 Mar.
[211]Department of Laboratory Medicine, Laboratory of Hematology of the Radboudumc and Radboud Institute for Molecular Life Sciences in Nijmegen, The Netherlands.2019 Oct.
[212]Patent. US20190248778A1.
[213]Oncotarget. 2017 Jul 18;8(29):47642-47654.
[214]Modern Oncology. 2017,25(01):0009-0013.
[215]Oncotarget. 2017 Jan 31;8(5):8536-8549.
[216]Patent. US20160368910A1.
[217]Graduate School of Arts & Sciences. Harvard University. 2016 Aug.
[218]Oncotarget. 2016 May 17;7(20):29131-42.
[219]Department of Dental Pharmacology. Okayama University. 2015.
[220]Patent. US20140309249A1.
[221]Chem Biol. 2012 Jan 27;19(1):140-54.
[222]Harvard Medical School LINCS LIBRARY

Summary

MK-2206 dihydrochloride (MK-2206 (2HCl)) is an orally active allosteric AKT inhibitor with IC ₅₀ s of 5 nM, 12 nM, and 65 nM for AKT1 , AKT2 , and AKT3 , respectively. MK-2206 dihydrochloride induces autophagy ^[1] ^[3] .

IC50 & Target

Akt1

8 nM (IC ₅₀ )

Akt2

12 nM (IC ₅₀ )

Akt3

65 nM (IC ₅₀ )

In Vitro

MK-2206 dihydrochloride (MK-2206 (2HCl)) (0-10 μM; 72 and 96 hours) inhibits the nasopharyngeal carcinoma (NPC) cell lines CNE-1, CNE-2, HONE-1, and SUNE-1 proliferation in dose- and time-dependent manner ^[1] .
MK-2206 dihydrochloride (0-10 μM; 24 and 48 hours) results in a dose-dependent increase in the percentage of cells in G0/G1 phase and a concomitant reduction of cell numbers in S phase in CNE-2 and HONE-1 cells ^[3] .
MK-2206 dihydrochloride (0-10 μM; 24 hours) attenuates phosphorylation levels of PRAS40 and S6 in a dose-dependent manner. MK-2206 does not effect phosphorylation of GSKα/β and AKT ^[3] .
MK-2206 dihydrochloride (0-10 μM; 24 hours) increases the appearance of LC3-II in CNE-2 cells dose-dependently. Microtubule-associated protein 1 LC3 is an essential autophagy protein ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay ^[3]

Cell Line:	The NPC cell lines CNE-1, CNE-2, HONE-1, and SUNE-1
Concentration:	0.08, 0.16, 0.31, 0.63, 1.25, 2.5, 5, 10 μM
Incubation Time:	72 and 96 hours
Result:	At 72 and 96 hours, the IC ₅₀ values in CNE-1, CNE-2, and HONE-1 cell lines were 3-5 μM, and in SUNE-1, they were less than 1 μM.

Cell Cycle Analysis ^[3]

Cell Line:	CNE-2 and HONE-1 cells
Concentration:	0.625, 1.25, 2.5, 5, 10 μM
Incubation Time:	24 or 48 hours
Result:	Induced cell cycle arrest at G1 in a dose-dependent manner.

Western Blot Analysis ^[3]

Cell Line:	SUNE-1 and CNE-2 cells
Concentration:	0.625, 1.25, 2.5, 5, 10 μM
Incubation Time:	24 hours
Result:	Inhibited phosphorylation of AKT downstream targets.

Cell Autophagy Assay ^[3]

Cell Line:	CNE-2 cells
Concentration:	0.625, 1.25, 2.5, 5, 10 μM
Incubation Time:	24 hours
Result:	Induced autophagy.

In Vivo

Both MK-2206 dihydrochloride (MK-2206 (2HCl)) doses (oral gavage; 480 mg/kg once a week and 240 mg/kg three times a week; for 2 weeks) can inhibit the growth of human CNE-2 xenografts in nude mice. No other obvious toxicity is observed in mice ^[3] .
MK-2206 dihydrochloride (orally; 120 mg/kg; alternate days; for 3 weeks) significantly inhibits tumor growth in 3-5 week old athymic nude mice with GEO colon carcinoma cells ^[4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Four- to 6-week-old male BALB/c nude mice with CNE-2 xenografts ^[3]
Dosage:	240 mg/kg and 480 mg/kg
Administration:	Oral gavage; 240 mg/kg for three times a week; 480 mg/kg for once a week; for 2 weeks
Result:	Both doses inhibited the growth of human CNE-2 xenografts in nude mice.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01369849	National Cancer Institute (NCI)	Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia	September 2011	Phase 1\|Phase 2
NCT01466868	Centre Leon Berard\|National Cancer Institute, France	Diffuse Large B Cell Lymphoma	November 2011	Phase 2
NCT01425879	National Cancer Institute (NCI)	Advanced Adult Hepatocellular Carcinoma\|Localized Non-Resectable Adult Liver Carcinoma\|Recurrent Adult Liver Carcinoma\|Recurrent Gallbladder Carcinoma\|Stage IV Distal Bile Duct Cancer\|Stage IV Gallbladder Cancer\|Unresectable Extrahepatic Bile Duct Carcinoma\|Unresectable Gallbladder Carcinoma	April 2011	Phase 2
NCT01349933	National Cancer Institute (NCI)	Recurrent Squamous Cell Carcinoma of the Nasopharynx\|Stage IV Squamous Cell Carcinoma of the Nasopharynx	April 2011	Phase 2
NCT01231919	National Cancer Institute (NCI)	Accelerated Phase Chronic Myelogenous Leukemia\|Acute Leukemias of Ambiguous Lineage\|Acute Myeloid Leukemia+Transient Myeloproliferative Disorder\|Acute Undifferentiated Leukemia\|Aggressive NK-cell Leukemia\|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative\|Blastic Phase Chronic Myelogenous Leukemia\|Blastic Plasmacytoid Dendritic Cell Neoplasm\|Childhood Burkitt Lymphoma\|Childhood Chronic Myelogenous Leukemia\|Childhood Diffuse Large Cell Lymphoma\|Childhood Grade III Lymphomatoid Granulomatosis\|Childhood Immunoblastic Large Cell Lymphoma\|Childhood Nasal Type Extranodal NK+T-cell Lymphoma\|Chronic Eosinophilic Leukemia\|Chronic Myelomonocytic Leukemia\|Chronic Neutrophilic Leukemia\|Chronic Phase Chronic Myelogenous Leukemia\|Intraocular Lymphoma\|Juvenile Myelomonocytic Leukemia\|Mast Cell Leukemia\|Myeloid+NK-cell Acute Leukemia\|Noncutaneous Extranodal Lymphoma\|Post-transplant Lymphoproliferative Disorder\|Primary Central Nervous System Hodgkin Lymphoma\|Primary Central Nervous System Non-Hodgkin Lymphoma\|Progressive Hairy Cell Leukemia, Initial Treatment\|Prolymphocytic Leukemia\|Recurrent Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Recurrent Childhood Anaplastic Large Cell Lymphoma\|Recurrent Childhood Grade III Lymphomatoid Granulomatosis\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Recurrent+Refractory Childhood Hodgkin Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Unspecified Childhood Solid Tumor, Protocol Specific\|Waldenström Macroglobulinemia	January 2011	Phase 1
NCT01319539	National Cancer Institute (NCI)	Estrogen Receptor Negative\|Estrogen Receptor Positive\|HER2+Neu Negative\|HER2+Neu Positive\|Progesterone Receptor Negative\|Progesterone Receptor Positive\|Stage IA Breast Cancer\|Stage IB Breast Cancer\|Stage IIA Breast Cancer\|Stage IIB Breast Cancer\|Stage IIIA Breast Cancer\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer\|Triple-Negative Breast Carcinoma	April 2011	Phase 2
NCT01283035	National Cancer Institute (NCI)	Ovarian Sarcoma\|Recurrent Fallopian Tube Carcinoma\|Recurrent Ovarian Carcinoma\|Recurrent Primary Peritoneal Carcinoma	April 2011	Phase 2
NCT01249105	Dana-Farber Cancer Institute\|Brigham and Women´s Hospital\|Massachusetts General Hospital\|Beth Israel Deaconess Medical Center\|Memorial Sloan Kettering Cancer Center\|University of California, Los Angeles\|Merck Sharp & Dohme LLC	Malignant Glioma		Phase 2
NCT01235897	University of California, San Francisco\|Merck Sharp & Dohme LLC	Advanced Solid Tumors\|Tumors\|Cancer	March 2011	Phase 1
NCT01239355	National Cancer Institute (NCI)	Adult Hepatocellular Carcinoma\|Advanced Adult Hepatocellular Carcinoma\|Localized Non-Resectable Adult Liver Carcinoma\|Recurrent Adult Liver Carcinoma	December 2010	Phase 2
NCT00670488	Merck Sharp & Dohme LLC	Locally Advanced Tumors\|Metastatic Solid Tumors\|Cancer\|Neoplasms	April 15, 2008	Phase 1
NCT01147211	National Taiwan University Hospital	Non Small Cell Lung Cancer	September 2010	Phase 1
NCT01243762	Merck Sharp & Dohme LLC	Neoplasms Malignant	November 22, 2010	Phase 1
NCT01071018	Merck Sharp & Dohme LLC	Solid Tumors	February 2010	Phase 1
NCT01306045	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Carcinoma, Non-Small-Cell Lung\|Carcinoma, Small Cell Lung\|Carcinoma, Thymic	February 8, 2011	Phase 2
NCT01295632	Merck Sharp & Dohme LLC	Advanced Cancer	February 2011	Phase 1
NCT01658943	National Cancer Institute (NCI)	Pancreatic Acinar Cell Carcinoma\|Pancreatic Ductal Adenocarcinoma\|Recurrent Pancreatic Carcinoma\|Stage IV Pancreatic Cancer	August 2012	Phase 2
NCT01281163	National Cancer Institute (NCI)	Estrogen Receptor Negative\|Estrogen Receptor Positive\|HER2+Neu Positive\|Progesterone Receptor Negative\|Progesterone Receptor Positive\|Recurrent Breast Carcinoma\|Stage IV Breast Cancer	January 2011	Phase 1
NCT01253447	National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia	October 2010	Phase 2
NCT01776008	National Cancer Institute (NCI)	Estrogen Receptor Positive\|HER2+Neu Negative\|Recurrent Breast Carcinoma\|Stage IIA Breast Cancer\|Stage IIB Breast Cancer\|Stage IIIA Breast Cancer\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer	January 2013	Phase 2
NCT01240941	Vanderbilt-Ingram Cancer Center	Metastatic Breast Cancer	February 2011	Phase 2
NCT01333475	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Colorectal Neoplasms	March 2011	Phase 2
NCT01186705	Memorial Sloan Kettering Cancer Center\|Merck Sharp & Dohme LLC	Colon Cancer\|Rectal Cancer	August 2010	Phase 2
NCT01294306	National Cancer Institute (NCI)	Adenosquamous Lung Carcinoma\|Bronchioloalveolar Carcinoma\|Large Cell Lung Carcinoma\|Lung Adenocarcinoma\|Recurrent Non-Small Cell Lung Carcinoma\|Squamous Cell Lung Carcinoma	February 2011	Phase 2
NCT01021748	Merck Sharp & Dohme LLC\|AstraZeneca	Locally Advanced or Metastatic Solid Tumors	November 23, 2009	Phase 1
NCT01307631	National Cancer Institute (NCI)	Endometrial Adenocarcinoma\|Endometrial Adenosquamous Carcinoma\|Endometrial Clear Cell Adenocarcinoma\|Endometrial Serous Adenocarcinoma\|Recurrent Uterine Corpus Carcinoma	March 2011	Phase 2
NCT01248247	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC\|National Cancer Institute (NCI)\|GlaxoSmithKline\|Novartis	Lung Cancer	June 2, 2011	Phase 2
NCT01251861	National Cancer Institute (NCI)	Recurrent Prostate Carcinoma\|Stage I Prostate Cancer AJCC v7\|Stage IIA Prostate Cancer AJCC v7\|Stage IIB Prostate Cancer AJCC v7\|Stage III Prostate Cancer AJCC v7	December 23, 2010	Phase 2
NCT01604772	National Cancer Institute (NCI)	Recurrent Oral Cavity Adenoid Cystic Carcinoma\|Recurrent Salivary Gland Carcinoma\|Salivary Gland Adenoid Cystic Carcinoma\|Stage IVA Major Salivary Gland Cancer AJCC v7\|Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7\|Stage IVB Major Salivary Gland Cancer AJCC v7\|Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7\|Stage IVC Major Salivary Gland Cancer AJCC v7\|Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7	July 23, 2012	Phase 2
NCT01344031	National Cancer Institute (NCI)	Estrogen Receptor Positive\|Invasive Breast Carcinoma\|Recurrent Breast Carcinoma\|Stage IV Breast Cancer AJCC v6 and v7	April 21, 2011	Phase 1
NCT01263145	National Cancer Institute (NCI)	Adult Solid Neoplasm\|Recurrent Breast Carcinoma\|Stage IV Breast Cancer	January 5, 2011	Phase 1
NCT00963547	Merck Sharp & Dohme LLC	Advanced Solid Tumors\|Breast Cancer	September 15, 2009	Phase 1
NCT01042379	QuantumLeap Healthcare Collaborative	Breast Neoplasms\|Breast Cancer\|Breast Tumors\|Angiosarcoma\|TNBC - Triple-Negative Breast Cancer\|HER2-positive Breast Cancer\|HER2-negative Breast Cancer\|Hormone Receptor Positive Tumor\|Hormone Receptor Negative Tumor\|Early-stage Breast Cancer\|Locally Advanced Breast Cancer	March 1, 2010	Phase 2
NCT01260701	National Cancer Institute (NCI)	Adenocarcinoma of the Gastroesophageal Junction\|Diffuse Gastric Adenocarcinoma\|Gastric Intestinal Type Adenocarcinoma\|Gastric Mixed Adenocarcinoma\|Recurrent Gastric Carcinoma	January 2011	Phase 2
NCT01783171	National Cancer Institute (NCI)	Pancreatic Adenocarcinoma\|Recurrent Pancreatic Carcinoma\|Stage III Pancreatic Cancer AJCC v6 and v7\|Stage IV Pancreatic Cancer AJCC v6 and v7\|Unresectable Pancreatic Carcinoma	January 15, 2013	Phase 1
NCT00848718	Merck Sharp & Dohme LLC	Locally Advanced, Metastatic Solid Tumors	March 17, 2009	Phase 1
NCT01859182	National Cancer Institute (NCI)	Adenocarcinoma of the Gallbladder\|Adenocarcinoma With Squamous Metaplasia of the Gallbladder\|Adult Primary Cholangiocellular Carcinoma\|Advanced Adult Primary Liver Cancer\|Cholangiocarcinoma of the Extrahepatic Bile Duct\|Localized Unresectable Adult Primary Liver Cancer\|Metastatic Extrahepatic Bile Duct Cancer\|Recurrent Adult Primary Liver Cancer\|Recurrent Extrahepatic Bile Duct Cancer\|Stage II Gallbladder Cancer\|Stage IIIA Gallbladder Cancer\|Stage IIIB Gallbladder Cancer\|Stage IVA Gallbladder Cancer\|Stage IVB Gallbladder Cancer\|Unresectable Extrahepatic Bile Duct Cancer	January 2013	Phase 2
NCT01277757	National Cancer Institute (NCI)	Recurrent Breast Carcinoma\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer\|Stage IV Breast Cancer	March 2011	Phase 2
NCT01519427	National Cancer Institute (NCI)	Recurrent Melanoma\|Stage IIIA Melanoma\|Stage IIIB Melanoma\|Stage IIIC Melanoma\|Stage IV Melanoma	January 2012	Phase 2
NCT01480154	National Cancer Institute (NCI)	Advanced Malignant Solid Neoplasm\|Stage III Cutaneous Melanoma AJCC v7\|Stage III Prostate Cancer AJCC v7\|Stage III Renal Cell Cancer AJCC v7\|Stage IIIA Cutaneous Melanoma AJCC v7\|Stage IIIB Cutaneous Melanoma AJCC v7\|Stage IIIC Cutaneous Melanoma AJCC v7\|Stage IV Cutaneous Melanoma AJCC v6 and v7\|Stage IV Prostate Cancer AJCC v7\|Stage IV Renal Cell Cancer AJCC v7	November 23, 2011	Phase 1
NCT01802320	National Cancer Institute (NCI)	Colon Mucinous Adenocarcinoma\|Colon Signet Ring Cell Adenocarcinoma\|Rectal Mucinous Adenocarcinoma\|Rectal Signet Ring Cell Adenocarcinoma\|Recurrent Colon Carcinoma\|Recurrent Rectal Carcinoma\|Stage IIIA Colon Cancer\|Stage IIIA Rectal Cancer\|Stage IIIB Colon Cancer\|Stage IIIB Rectal Cancer\|Stage IIIC Colon Cancer\|Stage IIIC Rectal Cancer\|Stage IVA Colon Cancer\|Stage IVA Rectal Cancer\|Stage IVB Colon Cancer\|Stage IVB Rectal Cancer	March 2013	Phase 2
NCT01245205	National Cancer Institute (NCI)	HER2-positive Breast Cancer\|Male Breast Cancer\|Recurrent Breast Cancer\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer\|Stage IV Breast Cancer\|Unspecified Adult Solid Tumor, Protocol Specific	November 2010	Phase 1
NCT01370070	Chinese University of Hong Kong	Recurrent Nasopharyngeal Carcinoma	July 2011	Phase 2
NCT01705340	National Cancer Institute (NCI)	Adenocarcinoma of the Gastroesophageal Junction\|HER2-positive Breast Cancer\|Male Breast Cancer\|Recurrent Breast Cancer\|Recurrent Esophageal Cancer\|Recurrent Gastric Cancer\|Stage IIIC Breast Cancer\|Stage IIIC Esophageal Cancer\|Stage IIIC Gastric Cancer\|Stage IV Breast Cancer\|Stage IV Esophageal Cancer\|Stage IV Gastric Cancer	September 2012	Phase 1
NCT01481129	National Cancer Institute (NCI)	Diffuse Large B Cell Lymphoma	December 2011	Phase 2
NCT01239342	National Cancer Institute (NCI)	Metastatic Kidney Carcinoma\|Recurrent Renal Cell Carcinoma\|Stage III Renal Cell Cancer AJCC v7\|Stage IV Renal Cell Cancer AJCC v7	January 27, 2011	Phase 2
NCT01169649	Memorial Sloan Kettering Cancer Center\|Merck Sharp & Dohme LLC	PANCREAS\|Neuroendocrine	July 2010	Phase 2
NCT01258998	National Cancer Institute (NCI)	Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|B-cell Adult Acute Lymphoblastic Leukemia\|B-cell Chronic Lymphocytic Leukemia\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Hepatosplenic T-cell Lymphoma\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Hairy Cell Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|T-cell Adult Acute Lymphoblastic Leukemia\|T-cell Large Granular Lymphocyte Leukemia\|Testicular Lymphoma\|Waldenström Macroglobulinemia	December 2010	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 16.67 mg/mL ( 34.70 mM ; ultrasonic and warming and heat to 70°C)

H ₂ O : 3.57 mg/mL ( 7.43 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0816 mL	10.4082 mL	20.8164 mL
5 mM	0.4163 mL	2.0816 mL	4.1633 mL
10 mM	0.2082 mL	1.0408 mL	2.0816 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 20% SBE-β-CD in saline

Solubility: 25 mg/mL (52.04 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 1.67 mg/mL (3.48 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 1.67 mg/mL (3.48 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Li Yan, et al. Abstract #DDT01-1: MK-2206: A potent oral allosteric AKT inhibitor. 2009.
[2] Xing Y, et al. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 Jul 5;21(1):78.
[3] Zhao YY, et al. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Drug Des Devel Ther. 2014 Oct 10;8:1827-37.
[4] Agarwal E, et al. Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer. BMC Cancer. 2014 Mar 1;14:145.

Synonyms

1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-, hydrochloride (1:2)

MK 2206 dihydrochloride

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart